A0362
Adjuplex™ Vaccine Adjuvant
Concentrate, sterile
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.25
UNSPSC Code:
12352200
sterility
sterile
quality
NOT FOR HUMAN USE
shipped in
wet ice
storage temp.
2-8°C
General description
Adjuplex potentiates immune responses to vaccines without reactogenicity and has demonstrated superiority to alum, Freund′s adjuvant, Ribi-R730 and numerous other experimental adjuvants. In laboratory animals, Adjuplex has been shown to improve the protective immune response to a variety of experimental human vaccines including HIV, influenza, rotavirus and malaria.
Application
Adjuplex is suitable for use with all types of antigens such as whole organism (live or inactivated), protein, polysaccharide, DNA, virus vector, and VLP. It is suitable for all routes of administration including intramuscular, subcutaneous, intradermal, and mucosal including intranasal.
Adjuplex™ Vaccine Adjuvant has been used to study the effects of adjuvants for DNA vaccination.
Adjuplex™ Vaccine Adjuvant has been used to study the effects of adjuvants for DNA vaccination.
Preparation Note
One ml of Adjuplex is sufficient to formulate ten 0.5 ml doses of vaccine.
Other Notes
Adjuplex Vaccine Adjuvant is a non-denaturing adjuvant that does not contain oils, detergents, preservatives, or components of animal or bacterial origin. Adjuplex is is non-immunogenic and free of allergens, enzymes, mercury, aluminum, and other metals.
Legal Information
Adjuplex is a trademark of Advanced BioAdjuvants, LLC
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
Storage Class
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jane E Libbey et al.
Vaccine, 29(17), 3356-3362 (2010-09-21)
Experimental autoimmune encephalomyelitis (EAE) is an experimental model for multiple sclerosis. EAE can be induced by inoculation with central nervous system (CNS) proteins or peptides emulsified in complete Freund's adjuvant. Protection from EAE, enhancement of EAE or subclinical priming for
Cornelis J M Melief
Journal of immunotherapy (Hagerstown, Md. : 1997), 35(3), 215-216 (2012-03-17)
Here, we review a novel vaccine modality, characterized by the administration of long (23 to 45 amino acids) synthetic peptides in incomplete Freund's adjuvant (mineral oil based, Montanide ISA-51), delivered subcutaneously. Such vaccines were first demonstrated to be much more
Samantha Burton et al.
Journal of virology, 93(7) (2019-01-18)
The goals of preclinical HIV vaccine studies in nonhuman primates are to develop and test different approaches for their ability to generate protective immunity. Here, we compared the impact of 7 different vaccine modalities, all expressing the HIV-1 1086.C clade
Production of EV71 vaccine candidates.
Chong P, Hsieh SY, Liu CC, et al.
Human Vaccines & Immunotherapeutics, 8 (2012)
Rui Kong et al.
Cell, 178(3), 567-584 (2019-07-28)
The vaccine-mediated elicitation of antibodies (Abs) capable of neutralizing diverse HIV-1 strains has been a long-standing goal. To understand how broadly neutralizing antibodies (bNAbs) can be elicited, we identified, characterized, and tracked five neutralizing Ab lineages targeting the HIV-1-fusion peptide
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service